Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia

被引：0

作者：

Yutaka Shimazu

Toshio Kitawaki

Tadakazu Kondo

Akifumi Takaori-Kondo

机构：

[1] Graduate School of Medicine,Department of Hematology and Oncology

[2] Kyoto University,Department of Hematology

[3] Kobe City Medical Center General Hospital,undefined

来源：

Cancer Immunology, Immunotherapy | 2023年 / 72卷

关键词：

Acute lymphoblastic leukemia; Blinatumomab; Lymphocyte counts; Blast ratio; Predictive markers;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Blinatumomab is an immunotherapy drug approved for the treatment of acute lymphoblastic leukemia. Since not all patients respond to blinatumomab, markers are needed to predict the efficacy of blinatumomab in individual patients. We hypothesized that the pre-treatment blast-to-lymphocyte ratio would predict blinatumomab efficacy. To examine this possibility, we conducted a post hoc analysis using data from the TOWER Clinical Trials (NCT02013167). Multivariate analysis showed that, along with the treatment groups, each of the following was independently correlated with superior progression-free survival: salvage-treatment phase, allogeneic stem cell transplantation, and pre-treatment ratio of bone marrow blasts-to-peripheral blood lymphocytes < 25.

引用

页码：3861 / 3865

页数：4

共 40 条

[1]

Löffler A(2003)Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Leukemia 17 900-909

[2]

Gruen M(2002)Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int J Cancer 100 690-697

[3]

Wuchter C(2005)Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int J Cancer 115 98-104

[4]

Dreier T(2007)The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct Cancer Immunol Immunother 56 1551-1563

[5]

Lorenczewski G(2021)Blinatumomab-induced T cell activation at single cell transcriptome resolution BMC Genomics 22 1-16

[6]

Brandl C(2000)A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2098-2103

[7]

Hoffmann P(2014)Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia J Clin Oncol 32 4134-4140

[8]

Hofmeister R(2015)Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Lancet Oncol 16 57-66

[9]

Brischwein K(2017)Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia N Engl J Med 376 836-847

[10]

Brandl C(2015)Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies Expert Opin Biol Ther 15 895-908

← 1 2 3 4 →